Background HIV-1-infected patients vary considerably by their response to antiretroviral
treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. This …

Drug transporters are increasingly recognized to be important to drug disposition and response.
P‐glycoprotein, the encoded product of the human MDR1 (ABCB1) gene, is of particular …

Objective Limited information exists on the clinical usefulness of drug level monitoring for
efavirenz, a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI). The aim of this …

Objectives: Efavirenz is an effective antiretroviral agent, but central nervous system side
effects occur commonly, and population (racial) differences in pharmacokinetics and response …

Objectives To compare the use of co-medication, the potential drug–drug interactions (PDDIs)
and the effect on antiretroviral therapy (ART) tolerability and efficacy in HIV-infected …

The Swiss HIV Cohort Study (SHCS) provides a unique research platform for clinical,
translational, epidemiological, social and basic research. The SHCS was established in 1988. It is …

Combined antiretroviral treatments have significantly improved the morbidity and mortality
related to HIV infection, thus transforming HIV infection into a chronic disease; however, the …

The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has been
granted authorization or approval in several countries for the treatment of patients with mild …

Introduction The availability of potent antiretroviral therapy has transformed HIV infection
into a chronic disease such that people living with HIV (PLWH) have a near normal life …

Objective The reverse transcriptase inhibitor efavirenz is currently used at a fixed dose of 600
mg/d. However, dosage individualization based on plasma concentration monitoring might …